In the current study, our approach is to target PARP-1 in prostate cancer cells with a PARP-1 inhibitor (WC-DZ-Br) labeled with the Auger emitter bromine-77 ([77Br]Br-WC-DZ). Here, PARP1 is linked to prostate carcinoma.